12/10/26
Western Gd shortage hits MRI-contrast producers
London, 12 October (Argus) — Export controls on gadolinium have lifted global
prices and squeezed gadolinium oxide supply for gadolinium-based contrast agents
(GBCAs) used in magnetic resonance imaging (MRI). Atlantic gadolinium prices
have risen sharply since the start of 2026, driven by extremely tight supply and
strong demand from end markets including defence and medicine. Argus assessed
99.99-99.999pc gadolinium oxide prices at $2,500-3,000/kg cif Europe on 8
October, up by 708pc from $250-430/kg on 1 January. Gadolinium stocks in the
west have fallen sharply since export controls on gadolinium and six other heavy
rare earths were introduced on 4 April 2025. Some gadolinium has continued to
flow to the west for non-military purposes under export licences. Export
licences have been granted to many medical companies for a variety of controlled
materials. But even licensed gadolinium exports have fallen in recent months,
Argus has heard, which has pressured medical companies seeking secure GBCA
supplies. The supply squeeze has placed the four main western GBCA producers —
Bayer, Guerbet, Bracco and GE HealthCare — in an unprecedented position.
Gadolinium crucial for diagnostic medicine GBCAs have been essential to
diagnostic imaging since the first agent was approved in 1988. During an MRI, a
patient is injected with a GBCA to provide contrast that makes small
abnormalities visible. Contrast-enhanced MRIs are essential for cancer
treatment, vascular imaging and cardiac MRIs. Contrast is not necessary for some
diagnostic MRIs, but there is no widely available alternative for certain
conditions such as brain cancer. More than 60mn doses of gadolinium contrast
agents were administered worldwide in 2024, and more than 900mn have been
delivered globally since 1988. Historically, the medical industry has been able
to obtain rare earths material with comparative ease, even immediately after the
introduction of export controls last year. But the tightening squeeze on exports
is now starting to impact pharmaceutical groups. "Our company is actively
monitoring the situation and implementing mitigation measures to minimise the
impact on customers as much as possible," a Bayer representative told Argus .
Bayer said supplies of Gadavist (gadobutrol), the company's main contrast
offering, remain unaffected. When asked whether Bayer expects to meet demand for
Gadavist over the next 12 months if current feedstock supply conditions persist,
the representative declined to comment further. A second GBCA producer confirmed
that it is exploring alternative sources of gadolinium outside China.
Pharmaceutical companies enter western spot market With Chinese supply no longer
sufficient to meet demand, several major GBCA producers have entered the western
spot market for gadolinium oxide, multiple sellers told Argus . But gadolinium
oxide supply outside China is insufficient to meet pharmaceutical demand. The
ex-China gadolinium spot market is relatively illiquid because of tight supply.
Many traders see only upside after the dramatic price surge since April 2025 and
are unwilling to release material at current prices. The medical industry must
compete with deep-pocketed defence buyers for the limited amount of gadolinium
currently available in the west. Gadolinium is also used in military and nuclear
applications. "The shortage is not medical-specific. Larger trading companies
are asking for it, and we see a shortage all around," a trader told Argus .
Medical companies have long been aware of gadolinium supply vulnerabilities and
are pursuing alternatives. GE HealthCare, for example, is in the clinical trial
phase of research into a manganese-based alternative to GBCAs. GE HealthCare
identified supply security as one of the benefits of a manganese contrast agent.
"As a rare-earth element, gadolinium supply is largely dependent on mining and
processing infrastructure in China. Manganese, however, is abundantly available
from multiple countries, including South Africa, Australia and Gabon, reducing
the risk of supply challenges impacting patient care," the company said in an
April statement announcing the start of the clinical trial. Advances that reduce
the amount of gadolinium needed per dose are already offering some potential
relief. On 15 June, the US Food and Drug Administration (FDA) approved Bayer's
Ambelvist (gadoquatrane), a contrast agent that Bayer described as the
lowest-dose macrocyclic GBCA in the US. In the near term, there is no indication
that export controls on gadolinium will be loosened. But the western spot market
cannot supply enough gadolinium to meet medical demand. If gadolinium exports to
the western medical sector do not rise, GBCA costs may skyrocket and patients
may face a shortage of a critical, life-saving diagnostic tool. By Maeve
Flaherty Send comments and request more information at feedback@argusmedia.com
Copyright © 2026. Argus Media group . All rights reserved.
